Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01482728 · ClinicalTrials.gov registry record · Early Phase 1
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer
A Early Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT01482728 is a Early Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 12 participants.
The verdict
NCT01482728, a Early Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the investigators can measure inhibition of a protein, Src (named for Sarcoma), in tissue and blood in patients with a diagnosis of endometrial cancer. Dasatinib is a drug that blocks the activity of an important protein in cancer cells called Src. The investigators can measure the blocking of Src in the bloodstream. However, the investigators do not know if measures in the bloodstream reflect blockage of Src in cancer tissue. The investigators are doing this study to try and see if the investigators can match what the investigators see in cancer tissue to what the investigators see in the bloodstream. the investigators hope that in the future, the investigators can use blood to measure protein inhibition by dasatinib instead of asking patients to undergo repeat biopsies.
Interventions
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01482728
The ClinicalTrials.gov registry entry for NCT01482728 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib is the first listed.
NCT01482728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01482728 about?
NCT01482728 is a clinical study titled "Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer". The purpose of this study is to see if the investigators can measure inhibition of a protein, Src (named for Sarcoma), in tissue and blood in patients with a diagnosis of endometrial cancer. Dasatinib is a drug that blocks the activity of an important protein in cancer cells called Src. The investig...
What is the current status of trial NCT01482728?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2012-01. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01482728?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT01482728?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.